Cyperus
Contrario Medical, Inc. · Decision date Oct 26, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Cyperus, a 510(k) submitted by Contrario Medical, Inc. of Houston, Texas, under number K262276. The decision date is 26 October 2026 and the application was received 6 July 2026. The device is classified as labware for assisted reproduction under regulation 21 CFR 884.6160, product code MQK, in the Obstetrics/Gynecology specialty and review panel. The record lists a traditional summary, no third-party review, no combination product status and no authorized predetermined change control plan.
SESE in the 510(k) pathway means the device was cleared as substantially equivalent to a predicate; it is not a premarket approval. The public record does not describe Cyperus's components, materials, intended use, predicate device or performance data, and no summary statement is included in the public information. The RSS listing confirms the same clearance and applicant. Whether the device is a new instrument or a modification of an existing product cannot be determined from these fields.
Readers should treat the clearance as a regulatory status only. No clinical, safety or comparative performance conclusions follow from the record, and the basis for the equivalence determination remains in FDA's underlying review documents, which were not provided here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Oct 26, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262276
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Contrario Medical, Inc.
- Product code
- MQK
- Decision code
- SESE
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Labware, Assisted Reproduction.
- Applicant
- Contrario Medical, Inc.
- Product code
- MQK
- FDA device class
- 2
FDA decision timeline
K262276 received
Application receipt date recorded by FDA.
K262276 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code MQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Pleiades DeviceK262066 | My123Baby Medical Limited Dba Boost Fertility | 510(k) clearance | Oct 30, 2026 | FDA |
Fertilis microICSI DeviceK262090 | Fertilis Pty, Ltd. | 510(k) clearance | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Contrario Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Houston, TX
Sources and methodology
- Original FDA record: K262276
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
